Reading HROW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HROW free→Reading HROW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HROW free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, HROW is below typical. Peer multiples imply a price about 138% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $38.93. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $39 HROW trades at 7× p/s — 2.8× the 3× p/s peer median. The market is re-rating it beyond its own range; our $14 fair value is low-confidence here. Analysts: $63–$88. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 181% near-term growth, well above our forecast of about 29%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -1.02x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.02 → $-0.23 (-1050.0% / 30d). 0 raised, 1 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$214.
How much price usually moves either way.
On a bad day, this stock has moved -$487.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,703.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the health care sector grows faster, it could help Harrow improve its performance.
Confirms:Health care sector revenue growth is speeding up again. It is now over 10% year over year.
Disproves:Sector revenue growth is slowing down. It is now below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HROW yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 11, 2026, Harrow, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the quarter ended March 31, 2026 and providing an update on recent corporate developments. The press release and letter to stockholders are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$63.00 – $88.00 (median $70.00) · 3 analysts · as of 2026-05-13
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
HROW Harrow, Inc. | Below typical Show detailsSector percentile: 11 of 100 | expensive | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain the full-year 2026 revenue guidance range of $350 million to $365 million.
Stated in 2 of last 2 quarters. Revenue for 2026-Q1 was $44.2M, down from $89.1M in 2025-Q4. The company maintains its full-year 2026 revenue guidance of $350M-$365M, but the trajectory shows limited progress toward this target given the Q1 revenue decline.
“Our full-year 2026 financial outlook remains entirely intact...”
“Full-year 2026 revenue guidance of $350 million to $365 million”
Maintain the full-year 2026 Adjusted EBITDA guidance range of $80 million to $100 million.
Stated in 2 of last 2 quarters. The company maintains its full-year 2026 Adjusted EBITDA guidance of $80M-$100M. However, with a Q1 operating loss of $22.1M, achieving this target will require significant improvement in subsequent quarters.
“We continue to expect... Adjusted EBITDA of $80 million to $100 million.”
Target revenue for Q2 2026 between $71 million and $81 million.
Newly stated in 2026-Q1. The company aims for Q2 2026 revenue of $71M-$81M. With Q1 revenue at $44.2M, achieving this target will require a substantial increase in sales, indicating a challenging trajectory.
“For the second quarter, we expect to report revenues between $71 million and $81 million.”
Why it matters: The earnings report will provide updates on revenue and losses. Investors will look for signs of improvement.
Confirms one read:An announcement of the next earnings report date within the next month.
Confirms the other:No date for the earnings report has been announced. This shows ongoing uncertainty.
Entry Into a Material Definitive Agreement Purchase Agreement On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers named therein (collectively, the “Initial Purchasers”), in connection with its offer and sale of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”). The terms of the New Notes sold purs…
Other Events. On March 27, 2026, the Company completed the sale of the New Notes in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act. The Company received net proceeds from the Offering, after…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Other Events. On March 24, 2026, Harrow, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $50.0 million aggregate principal amount of additional 8.625% Senior Notes due 2030 (the “New Notes”) in a private offering (the “Offering”) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the…
“Full-year 2026 Adjusted EBITDA guidance of $80 million to $100 million”